4] surfactant to mitigate the effects of acute radiation exposure
to the lung, including acute pneumonitis and delayed lung injury.
Two treatment conditions were used throughout the experiments: a) continuous low dose-rate radiation, and b) acute radiation exposure
A new class of pharmaceutical that promises to protect patients from acute radiation exposure
has been developed.
Note that one must be exposed to something in the area of 100,000 mrems of radiation in a short period to suffer symptoms of acute radiation exposure
, and even more than that to risk death.
In the aftermath of the nuclear meltdown at Chernobyl, 56 people died from acute radiation exposure
Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to investigate preclinically the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure
It is also being developed, with up to $140 million in funding by the US Government, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure
This effect is known as a delayed effect of acute radiation exposure
Pharmaceuticals are also in development to facilitate immune system recovery after damage from chemotherapy or acute radiation exposure
New contracts fund drugs for skin and lung injuries associated with acute radiation exposure
population against acute radiation exposure
resulting from a nuclear terrorist attack or accident.
Radiation-induced pneumonits and/or fibrosis are potentially lethal delayed effects of acute radiation exposure